Welcome to LookChem.com Sign In|Join Free
  • or
AZD 8329 is a novel, potent, and selective small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family, which plays a crucial role in various cellular processes, including cell proliferation, differentiation, and survival. This chemical has shown promise in the treatment of various cancers, particularly those with FGFR mutations or amplifications, such as bladder, breast, lung, and gastric cancers. By targeting the FGFR pathway, AZD 8329 aims to inhibit tumor growth and progression, making it a potential therapeutic option for patients with FGFR-driven malignancies.

1048668-70-7

Post Buying Request

1048668-70-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1048668-70-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1048668-70-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,8,6,6 and 8 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1048668-70:
(9*1)+(8*0)+(7*4)+(6*8)+(5*6)+(4*6)+(3*8)+(2*7)+(1*0)=177
177 % 10 = 7
So 1048668-70-7 is a valid CAS Registry Number.

1048668-70-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[4-(1-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl]benzoic acid

1.2 Other means of identification

Product number -
Other names UNII-5B38CV1212

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1048668-70-7 SDS

1048668-70-7Downstream Products

1048668-70-7Relevant academic research and scientific papers

A greener approach for the large-scale synthesis of 1,4,5-trisubstituted pyrazole, AZD8329

Rangappa, Paramashivappa,Ghosh, Avipsa,Chitrapadi, Smitha,Kantikar, Gajanan,Ch, Vinod Kumar,Sythana, Sureshkumar,Manjunath, Sulur G.,Nambiar, Sudhir,Sridhran

, p. 947 - 951 (2014)

The development of a convenient, safe and scalable process for AZD8329 manufacturing is reported here. Synthesis was achieved in a two-step telescopic process with an excellent overall yield of 75%. In the first step enamine (6) was synthesized with 90% yield through three chemical transformations. In the next step AZD8329 was synthesized from the reactions of 6 and 4-hydrazinobenzoic acid hydrochloride 7 through two chemical transformations. The process is very efficient and economical, and AZD8329 was manufactured in multikilogram scale. A greener approach is demonstrated through usage of a minimum number of solvents and energy and with process mass intensity (PMI) 60 in the manufacturing process.

Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: The discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329)

Scott, James S.,Deschoolmeester, Joanne,Kilgour, Elaine,Mayers, Rachel M.,Packer, Martin J.,Hargreaves, David,Gerhardt, Stefan,Ogg, Derek J.,Rees, Amanda,Selmi, Nidhal,Stocker, Andrew,Swales, John G.,Whittamore, Paul R.O.

, p. 10136 - 10147 (2013/01/16)

Inhibition of 11β-HSD1 is viewed as a potential target for the treatment of obesity and other elements of the metabolic syndrome. We report here the optimization of a carboxylic acid class of inhibitors from AZD4017 (1) to the development candidate AZD8329 (27). A structural change from pyridine to pyrazole together with structural optimization led to an improved technical profile in terms of both solubility and pharmacokinetics. The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a reduction in lipophilicity leading to an overall increase in metabolic stability.

NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597

-

Page/Page column 25-26, (2010/08/09)

A process for preparing pharmaceutically acceptable compounds of formula (I) wherein R1, R2, R3, X, A and Y are as defined in the specification is described and claimed, together with processes for preparing some key inter

PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS

-

Page/Page column 59-60, (2008/12/08)

A compound of formula (I): and pharmaceutically -acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1048668-70-7